Medical devices, healthcare technology and the business of care
PMA approval · P030005

CONTAK RENEWAL MODELS H125 AND H120 WITH THE MODEL 2865 VERSION 1.8 APPLICATION SOFTWARE

Guidant Corp. · Decision date Jan 26, 2004

MEDTECHLEDGER EXPLANATIONP030005

What did the FDA approve?

FDA approved the CONTAK RENEWAL TR pulse generator on January 26, 2004. The approval statement lists an indication for patients with moderate to severe heart failure (NYHA Class III/IV), left ventricular dysfunction with EF <= 35%, QRS duration >= 120 ms, and symptoms persisting despite stable, optimal heart failure drug therapy as defined in the clinical trials section.

The device provides atrial-ventricular tracking modes to help preserve AV synchrony and adaptive-rate pacing for patients who would benefit from adjusted pacing rates concurrent with physical activity. The statement reports these device purposes but does not itself present independent proof of safety or clinical effectiveness. The record does not describe any supplement type or reason.

FDA approval order statement

APPROVAL FOR THE CONTAK RENEWAL TR. THE DEVICE IS INDICATED S FOLLOWS: THE CONTAK RENEWAL TR PULSE GENERATOR IS INDICATED FOR PATIENTS WHO HAVE MODERATE TO SEVERE HEART FAILURE (NYHA CLASS III/IV) INCLUDING LEFT VENTRICULAR DYSFUNCTION (EF <= 35%) AND QRS DURATION >= 120 MS AND REMAIN SYMPTOMATIC DESPITE STABLE, OPTIMAL HEART FAILURE DRUG THERAPY (AS DEFINED IN THE CLINICAL TRIALS SECTION). THE DEVICE PROVIDES ATRIAL-VENTRICULAR TRACKING MODES TO HELP PRESERVE AV SYNCHRONY, AND ADAPTIVE-RATE PACING FOR PATIENTS WHO WOULD BENEFIT FROM ADJUSTED PACING RATES CONCURRENT WITH PHYSICAL ACTIVITY.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Jan 26, 2004

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P030005
Regulatory pathway
Premarket approval application
Applicant
Guidant Corp.
Product code
NKE
Decision code
APPR
Decision date
Jan 26, 2004
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).

Applicant
Guidant Corp.
Product code
NKE
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P030005 received

    Application receipt date recorded by FDA.

  2. P030005 · FDA decision

    APPR

  3. P030005/S257 · Related supplement

    VALITUDE (Model U125); VALITUDE X4 (Model U128); VISIONIST (Models U225, U226); VISIONIST X4 (Model U228)

Timeline entries are records held by MedtechLedger for P030005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030005

Product / regulatory recordCompanyPathwayDecision dateSource
Guidant Corp.PMA supplementOct 3, 2026FDA

Explore the linked device profile

Other records with product code NKE

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Guidant Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records